Silent artery risk: new study screens diabetic kidney patients for hidden heart danger
NCT ID NCT07266220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will use a safe ultrasound test to look for early signs of artery hardening in 96 adults who have both type 2 diabetes and stage 3 chronic kidney disease. Many patients with these conditions develop heart problems without symptoms. The goal is to find out how common these hidden artery changes are and how they relate to kidney function and blood sugar control, which could help doctors prevent future heart attacks and strokes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 96 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with type 2 diabetes mellitus and stage 3 chronic kidney disease recruited from the nephrology and internal medicine outpatient clinics and inpatient wards of Assiut University Hospitals.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
1. Age≥18years. 2. Diagnosis of type 2 diabetes mellitus (per treating physician or ADA criteria). 3. CKDstage3:eGFR30-59mL/min/1.73 m² on at least two measurements ≥3 months apart OR established diagnosis in medical record. 4. Clinically stable (no AKI, no hospitalization for cardiovascular event in past 3 months). 5. Ableandwilling to provide informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- Can a vegan diet shield police officers from heart disease?
- Can a health coach in your patient portal help you lose weight?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?